Rho GTPase RhoJ is associated with gastric cancer progression and metastasis

Chan Kim, Hannah Yang, Intae Park, Hong Jae Chon, Joo Hoon Kim, Woo Sun Kwon, Won Suk Lee, Tae Soo Kim, SunYoung Rha

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Rho GTPases play a pivotal role in tumor progression by regulating tumor cell migration and invasion. However, the role of Rho GTPases in gastric cancer (GC) remains unexplored. This study aimed to investigate the clinical implications of RhoJ, which is an uncharted member of Rho family. RhoJ expression in human GC cell lines and surgical specimens from GC patients were analyzed. Moreover, in vitro gain-of-function analysis was performed to evaluate the malignant phenotypes of RhoJ-overexpressing GC cells. The extent of RhoJ expression varied among GC cell lines and GC patients. YCC-9 cell line displayed the strongest expression, while YCC-10, -11, and -16 showed scant expressions. Of the 70 GC patients, 34 (48.6%) had RhoJ expression in their GC tissue, and patients with high RhoJ expression had more diffuse type GC (73.5% vs. 41.7%), were at more advanced stages (stage III, IV: 85.3% vs. 58.4%), and had more frequent metastasis (47.1% vs. 11.1%), denoting that RhoJ has a potential role in GC progression and metastasis. High RhoJ expression significantly correlated with poor overall survival and recurrence-free survival after surgical resection of gastric cancer. Finally, In vitro gain-of-function experiments showed 41.3% enhanced motility and 60.4% enhanced invasiveness in RhoJ-overexpressing GC cells compared to control, with negligible difference in cell proliferation. Collectively, high RhoJ expression is an independent negative prognostic factor for the survival outcome of GC and correlated with the increased cell motility and invasiveness.

Original languageEnglish
Pages (from-to)1550-1556
Number of pages7
JournalJournal of Cancer
Volume7
Issue number11
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

rho GTP-Binding Proteins
Stomach Neoplasms
Neoplasm Metastasis
Cell Line
Cell Movement
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, C., Yang, H., Park, I., Chon, H. J., Kim, J. H., Kwon, W. S., ... Rha, S. (2016). Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. Journal of Cancer, 7(11), 1550-1556. https://doi.org/10.7150/jca.15578
Kim, Chan ; Yang, Hannah ; Park, Intae ; Chon, Hong Jae ; Kim, Joo Hoon ; Kwon, Woo Sun ; Lee, Won Suk ; Kim, Tae Soo ; Rha, SunYoung. / Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. In: Journal of Cancer. 2016 ; Vol. 7, No. 11. pp. 1550-1556.
@article{f67743c8b07a46a09f22b24073253820,
title = "Rho GTPase RhoJ is associated with gastric cancer progression and metastasis",
abstract = "Rho GTPases play a pivotal role in tumor progression by regulating tumor cell migration and invasion. However, the role of Rho GTPases in gastric cancer (GC) remains unexplored. This study aimed to investigate the clinical implications of RhoJ, which is an uncharted member of Rho family. RhoJ expression in human GC cell lines and surgical specimens from GC patients were analyzed. Moreover, in vitro gain-of-function analysis was performed to evaluate the malignant phenotypes of RhoJ-overexpressing GC cells. The extent of RhoJ expression varied among GC cell lines and GC patients. YCC-9 cell line displayed the strongest expression, while YCC-10, -11, and -16 showed scant expressions. Of the 70 GC patients, 34 (48.6{\%}) had RhoJ expression in their GC tissue, and patients with high RhoJ expression had more diffuse type GC (73.5{\%} vs. 41.7{\%}), were at more advanced stages (stage III, IV: 85.3{\%} vs. 58.4{\%}), and had more frequent metastasis (47.1{\%} vs. 11.1{\%}), denoting that RhoJ has a potential role in GC progression and metastasis. High RhoJ expression significantly correlated with poor overall survival and recurrence-free survival after surgical resection of gastric cancer. Finally, In vitro gain-of-function experiments showed 41.3{\%} enhanced motility and 60.4{\%} enhanced invasiveness in RhoJ-overexpressing GC cells compared to control, with negligible difference in cell proliferation. Collectively, high RhoJ expression is an independent negative prognostic factor for the survival outcome of GC and correlated with the increased cell motility and invasiveness.",
author = "Chan Kim and Hannah Yang and Intae Park and Chon, {Hong Jae} and Kim, {Joo Hoon} and Kwon, {Woo Sun} and Lee, {Won Suk} and Kim, {Tae Soo} and SunYoung Rha",
year = "2016",
month = "1",
day = "1",
doi = "10.7150/jca.15578",
language = "English",
volume = "7",
pages = "1550--1556",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "11",

}

Kim, C, Yang, H, Park, I, Chon, HJ, Kim, JH, Kwon, WS, Lee, WS, Kim, TS & Rha, S 2016, 'Rho GTPase RhoJ is associated with gastric cancer progression and metastasis', Journal of Cancer, vol. 7, no. 11, pp. 1550-1556. https://doi.org/10.7150/jca.15578

Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. / Kim, Chan; Yang, Hannah; Park, Intae; Chon, Hong Jae; Kim, Joo Hoon; Kwon, Woo Sun; Lee, Won Suk; Kim, Tae Soo; Rha, SunYoung.

In: Journal of Cancer, Vol. 7, No. 11, 01.01.2016, p. 1550-1556.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rho GTPase RhoJ is associated with gastric cancer progression and metastasis

AU - Kim, Chan

AU - Yang, Hannah

AU - Park, Intae

AU - Chon, Hong Jae

AU - Kim, Joo Hoon

AU - Kwon, Woo Sun

AU - Lee, Won Suk

AU - Kim, Tae Soo

AU - Rha, SunYoung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Rho GTPases play a pivotal role in tumor progression by regulating tumor cell migration and invasion. However, the role of Rho GTPases in gastric cancer (GC) remains unexplored. This study aimed to investigate the clinical implications of RhoJ, which is an uncharted member of Rho family. RhoJ expression in human GC cell lines and surgical specimens from GC patients were analyzed. Moreover, in vitro gain-of-function analysis was performed to evaluate the malignant phenotypes of RhoJ-overexpressing GC cells. The extent of RhoJ expression varied among GC cell lines and GC patients. YCC-9 cell line displayed the strongest expression, while YCC-10, -11, and -16 showed scant expressions. Of the 70 GC patients, 34 (48.6%) had RhoJ expression in their GC tissue, and patients with high RhoJ expression had more diffuse type GC (73.5% vs. 41.7%), were at more advanced stages (stage III, IV: 85.3% vs. 58.4%), and had more frequent metastasis (47.1% vs. 11.1%), denoting that RhoJ has a potential role in GC progression and metastasis. High RhoJ expression significantly correlated with poor overall survival and recurrence-free survival after surgical resection of gastric cancer. Finally, In vitro gain-of-function experiments showed 41.3% enhanced motility and 60.4% enhanced invasiveness in RhoJ-overexpressing GC cells compared to control, with negligible difference in cell proliferation. Collectively, high RhoJ expression is an independent negative prognostic factor for the survival outcome of GC and correlated with the increased cell motility and invasiveness.

AB - Rho GTPases play a pivotal role in tumor progression by regulating tumor cell migration and invasion. However, the role of Rho GTPases in gastric cancer (GC) remains unexplored. This study aimed to investigate the clinical implications of RhoJ, which is an uncharted member of Rho family. RhoJ expression in human GC cell lines and surgical specimens from GC patients were analyzed. Moreover, in vitro gain-of-function analysis was performed to evaluate the malignant phenotypes of RhoJ-overexpressing GC cells. The extent of RhoJ expression varied among GC cell lines and GC patients. YCC-9 cell line displayed the strongest expression, while YCC-10, -11, and -16 showed scant expressions. Of the 70 GC patients, 34 (48.6%) had RhoJ expression in their GC tissue, and patients with high RhoJ expression had more diffuse type GC (73.5% vs. 41.7%), were at more advanced stages (stage III, IV: 85.3% vs. 58.4%), and had more frequent metastasis (47.1% vs. 11.1%), denoting that RhoJ has a potential role in GC progression and metastasis. High RhoJ expression significantly correlated with poor overall survival and recurrence-free survival after surgical resection of gastric cancer. Finally, In vitro gain-of-function experiments showed 41.3% enhanced motility and 60.4% enhanced invasiveness in RhoJ-overexpressing GC cells compared to control, with negligible difference in cell proliferation. Collectively, high RhoJ expression is an independent negative prognostic factor for the survival outcome of GC and correlated with the increased cell motility and invasiveness.

UR - http://www.scopus.com/inward/record.url?scp=84994371732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994371732&partnerID=8YFLogxK

U2 - 10.7150/jca.15578

DO - 10.7150/jca.15578

M3 - Article

VL - 7

SP - 1550

EP - 1556

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 11

ER -

Kim C, Yang H, Park I, Chon HJ, Kim JH, Kwon WS et al. Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. Journal of Cancer. 2016 Jan 1;7(11):1550-1556. https://doi.org/10.7150/jca.15578